What’s Propelling OncoSec Medical Inc (ONCS) to Decrease? The Stock Formed a Double Bottom Pattern

September 17, 2017 - By Marie Mckinney

The chart of OncoSec Medical Inc (ONCS) shows a double bottom with $0.88 target or 8.00 % below today’s $0.96 share price. The 9 months chart pattern indicates high risk for the $20.32 million company. It was reported on Sep, 17 by Finviz.com. If the $0.88 price target is reached, the company will be worth $1.63 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 3.03% or $0.03 on September 15, reaching $0.96. About 115,091 shares traded or 1.38% up from the average. OncoSec Medical Inc (NASDAQ:ONCS) has declined 34.57% since September 17, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

Wall Street await OncoSec Medical Inc (NASDAQ:ONCS) to release earnings on October, 12. Analysts forecast earnings per share of $-0.23, up exactly $0.16 or 41.03 % from 2014’s $-0.39 EPS. After posting $-0.22 EPS for the previous quarter, OncoSec Medical Inc’s analysts now forecast 4.55 % negative EPS growth.

OncoSec Medical Inc (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 7 analyst reports since March 9, 2016 according to SRatingsIntel. On Friday, June 2 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Buy” rating by Noble Financial on Tuesday, June 13. The firm earned “Buy” rating on Thursday, June 8 by Maxim Group. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 9. The firm has “Buy” rating by H.C. Wainwright given on Monday, June 12. The rating was maintained by H.C. Wainwright with “Buy” on Friday, June 2. The stock of OncoSec Medical Inc (NASDAQ:ONCS) earned “Buy” rating by Rodman & Renshaw on Thursday, July 21.

More notable recent OncoSec Medical Inc (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer” on September 06, 2016, also Seekingalpha.com with their article: “Inovio Pharmaceuticals And OncoSec Medical: Putting The Pieces Together” published on December 15, 2015, Prnewswire.com published: “OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at …” on March 21, 2017. More interesting news about OncoSec Medical Inc (NASDAQ:ONCS) were released by: Thestreet.com and their article: “Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot” published on March 03, 2017 as well as Prnewswire.com‘s news article titled: “OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017” with publication date: May 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.